绥美凯（Inbec）注意事项

(Inbec) is mainly used to treat adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). It can help patients prolong their survival time and improve their quality of life. Patients need to understand the precautions while taking Inbec to avoid interactions between drugs and cause harm to the body. Today we will learn about Inbec’s precautions.

1. Overeating and overeating are taboo: During the eating process, patients must avoid overeating and eat small meals frequently to avoid aggravating the burden on the gastrointestinal tract and causing other complications. 

2. Transmission of HIV: Although effective suppression of the virus with antiretroviral treatment has been shown to significantly reduce the risk of sexual transmission, residual risks cannot be ruled out. Precautions should be taken to prevent transmission in accordance with national guidance. 

3. Hypersensitivity Reaction: Both abacavir and dolutegravir carry the risk of triggering a hypersensitivity reaction (HSR) and share some common characteristics, such as fever and/or rash and other symptoms indicating involvement of multiple organs. It is clinically impossible to determine whether abacavir or dolutegravir is responsible for a hypersensitivity reaction occurring with the use of this product. Hypersensitivity reactions have been observed to occur more commonly with abacavir, some of which can be life-threatening and, in rare cases, fatal if not managed appropriately. Patients who test positive for the HLA-B5701 allele are at higher risk of developing abacavir hypersensitivity reactions. However, abacavir hypersensitivity reactions are reported less frequently in patients who do not carry this allele. 

4. HLA-B5701 status must be confirmed before starting treatment with Inbec. Patients with a positive HLA-B5701 status, or patients with a negative HLA-B5701 status who have had suspected abacavir hypersensitivity reactions when previously receiving abacavir-containing treatment regimens, should not be treated with this product. 

5. If a hypersensitivity reaction is suspected after taking Inbec, even if the HLA-B5701 allele does not exist, the product should be stopped without delay. After a hypersensitivity reaction occurs, if treatment with this product is not stopped immediately, a life-threatening reaction may occur immediately. Clinical status, including hepatic aminotransferases and bilirubin, should be monitored.

  6. After discontinuing Inbec due to suspected hypersensitivity reaction, you must not re-use this product or any other medicine containing abacavir or dolutegravir. After a suspected hypersensitivity reaction to abacavir, symptoms may return within hours if abacavir-containing medicines are restarted. Relapses are generally more severe than the initial episode and may include life-threatening hypotension and death. To avoid re-dosing abacavir and dolutegravir, patients with suspected hypersensitivity reactions should be instructed to discard remaining Abacavir tablets.

The above is the content of (Inbec) precautions, I hope it can help you!